Connect with us

Cannabis News

Alaska Government Task Force Recommends Legalizing Psychedelic Therapy Upon FDA Approval

Published

3 weeks ago

on

An Alaska psychedelic task force is recommending that the state move forward with plans to provide regulated access to psychedelics if the federal Food and Drug Administration (FDA) allows medical use of substances such as psilocybin and MDMA.

According to a law approved in 2024, after working for about a year studying the issue, Alaska Legislative Task Force on Psychedelic Drug Regulation released its findings and recommendations on Thursday.

“Alaska has one of the nation’s highest rates of domestic violence survivors and combat veterans suffering from PTSD, and many Alaskans continue to struggle with traditional treatments,” Sen. Forrest Dunbar (D), the task force’s leader, said in a press release.

“Our approach to these new medical therapies must be properly and independently evaluated so that if the legislature were to make policy changes, we will do so with empirical data in a properly controlled environment,” the senator said.

The panel’s report lists a number of findings based on a review of the scientific literature and expert testimony. This includes findings that some psychedelics do indeed have “potential therapeutic uses” and that “there is a particular focus on the use of these therapies for veterans, survivors of assault and interpersonal violence, and others with post-traumatic stress disorder (PTSD).

Members emphasized the importance of delivering psychedelic therapies in partnership with “multiple types of providers” to provide comprehensive treatment, rather than leaving it up to the patient.

Among its recommendations, the task force said, “If psychedelic medical therapies are approved by the FDA, the state should take steps to allow them to be used in Alaska, rather than ban their use.”

Alaska regulators should also identify clinical task forces, “whose role is to regularly review up-to-date studies and the evidence base to make recommendations, and rely on those entities to provide ongoing guidance on the use of these therapies,” he said.

“As much as possible, reserve the use of state statute for broad enabling language and essential components of a regulatory structure, and leave most regulatory decisions to the appropriate boards and agencies,” another recommendation reads. “Regulations still require a robust public process to be approved, but they are more predictable and can be updated or changed more easily than statutory amendments that require legislative action.”

“The appropriate parameters for the use of these therapies are likely to change over time as the evidence base matures and FDA approval may be granted for multiple therapies,” he said.

If the FDA continues to approve any psychedelics for medical use, the panel said the Alaska State Board of Medicine should update its guidelines for prescribing controlled substances to include new therapies.

Additionally, if the FDA approves psychedelic drugs and the Drug Enforcement Administration (DEA) federally reschedules substances such as psilocybin, Alaska “should fully reflect federal programming and Risk Evaluation and Mitigation Strategies (REMS), without adding duplicative or conflicting state regulations, and follow the rules for determining whether a DEA license is required.” the report he says

“This approach respects federal science and facilitates access for patients and providers,” he continues.

Additionally, as lawmakers and regulators await a federal decision to advance psychedelic therapies, states should consider legislation to “incorporate the recommendations made in this report to encourage statewide implementation action.”

“Legislation on triggers would require addressing various process and regulatory issues, such as the role and involvement of professional licensing boards, state agencies, and the Controlled Substances Advisory Committee,” the task force said.

The report also says that psychedelic reform should include military veterans’ access to FDA-approved therapies, which could involve working with the US Department of Veterans Affairs (VA) to identify opportunities to participate in clinical trials and pilot programs using new drugs.

“The grant should be considered to ensure active efforts by the American Medical Association (AMA) and the Centers for Medicare and Medicaid Services (CMS) to develop billing codes that will promote sufficient reimbursement for the provision of psychedelic therapy, which are essential to ensure patient access post-FDA approval,” the panel said.

Rep. Justin Ruffridge (R), who also serves as co-chair of the psychedelic panel, said the task force “focused on preparing Alaska for potential federal approval of psychedelic therapies.”

“These recommendations came from months of collaboration and work by medical professionals, advocates and legislators who focused on patient safety, evidence-based care and access, especially for those who have not seen progress through traditional treatments,” he said.

So far two other states have facilitated fully functioning psychedelic programs. Oregon voters legalized the therapeutic psilocybin in 2020and Colorado’s program was approved at the ballot box in 2022, with the state’s governor signing the legislation a year later to create the regulatory framework for the program

Meanwhile, a campaign in Alaska announced in December that it did not get enough signaturesAn initiative to legalize some psychedelics like psilocybin and DMT on the 2026 state ballot.– but the activists have emphasized that “the work is far from over” as they focus on putting the reform measure before the voters in 2028.

“While we won’t be on the ballot in 2026, we’re still on track for 2028, and with the determination, focus and support of our community, we’ll continue to move forward,” Natural Medicine Alaska said in December. “This movement is gaining momentum every day. In fact, 65 percent of Alaskans support this initiative, and that number continues to grow.”

A pre-campaign policy outline explained that the proposal is “under construction”. The Natural Medicine Health Act of 2022 passed by Colorado votersunder last year facilitators administered the state’s first legal dose of psilocybin.

A 2024 poll found that nearly half (49.4 percent) of Alaskan adults would support a ballot measure more broadly. remove criminal penalties for the use of substances such as psilocybin mushrooms.

That support rose significantly—to nearly two-thirds (65 percent)—when participants were told that Alaska has high rates of mental illness that could be treated with psychedelics.

Photo elements courtesy of the user carlosemmaskype and Apollo.

Marihuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Related Topics:
Continue Reading

Cannabis News

Swiss company launches nationwide price comparison tool for cannabis

Published

11 hours ago

on

March 2, 2026

By











Evidena Care AG is one of the leading Swiss telemedicine platforms and specialized medical practices for medical cannabis. The company currently supports more than 2,000 patients across the country. Under the direction of Dr. Nicolai Berardi and two other specialist doctors, Evidena Care has focused on evidence-based, responsible and patient-centered treatment for the past two years.

Now, Evidena Care is launching a nationwide online comparison portal for medical cannabis products. The platform is designed for patients who already have a valid medical prescription and want a clear and reliable view of the market. For the first time in Switzerland, patients can directly compare products and prices from the country’s largest pharmacies in one place.

Medical cannabis plays an essential role in the treatment plans of many patients. At the same time, prices can vary significantly between pharmacies, even when the products contain the same levels of active ingredients. As these costs are often not covered by health insurance, or only partially covered, many patients have a heavy financial burden. The new portal addresses this issue by bringing transparency to a market that until now has been difficult to navigate.

The platform provides an overview of available products and dosages, clearly lists the active ingredient content, such as THC and CBD levels, and displays the current prices of leading Swiss pharmacies. Patients can directly compare options and make informed decisions that help optimize their therapy costs, without compromising medical guidance.

“Patients should not be victims of non-transparent pricing structures,” says Dr. Nicolai Berardi, CEO of Evidena Care AG. “We are creating transparency with our comparison portal, strengthening the self-responsibility of those affected and promoting fair competition in the interests of patients.”

The portal is only for people with a valid prescription. It serves as a true information tool and supports cost optimization in an existing therapy supervised by a physician.

For more information:
Evidena Care AG
Email: (email protected)
https://evidena.care/










Continue Reading

Cannabis News

Virginia Lawmakers Advance Marijuana Resentencing Bills As Push To Legalize Commercial Sales Also Nears Finish Line

Published

11 hours ago

on

March 2, 2026

By

Virginia’s House and Senate lawmakers have advanced a pair of bills with amendments that would allow people with prior marijuana convictions to be sentenced.

Members of the Senate and House Judiciary Committees on Monday approved alternate versions of the reform bill in opposite chambers, setting the stage for bicameral negotiations as the measures move through the legislative process.

Broadly, the legislation introduced in both chambers would create a process to consider changing the sentences for people incarcerated or on community supervision for certain crimes involving the possession, manufacture, sale or distribution of marijuana.

The Senate panel approved it HB 26 In a 9-6 vote by Del. Rozia Henson (D), with revisions largely consistent with the House bill, SB 62that is being backed by Senate President Pro Tem Louise Lucas (D). passed on the floor last month before going Home.

Senators have now referred the House measure to the Senate Finance and Appropriations Committee for further consideration.

There are some differences between the sizes of the chambers. The House-passed legislation includes minors who would be eligible for relief from marijuana-related convictions, clarifies that judges would only consider convictions for cannabis offenses and specifies that the reform would include people with marijuana-related probation violations.

Both proposed bills apply to people with convictions or convictions for conduct that occurred before July 1, 2021, when a state law legalizing personal possession and home cultivation of marijuana went into effect.




As for the Senate bill, which clean up The House committee’s 15-7 vote Monday would have eliminated more categories of people who could be eligible for the sentence as an alternative, and would add a longer list of violent crimes that make people with cannabis convictions ineligible for relief.

Against the background of these recent developments, Virginia bills to legalize the sale of recreational marijuana have moved forward in the way of implementing laws. Last week, members of the Chamber of Deputies and the Senate modified and advanced the proposals of the opposite chambers on the subject.

Members of the Virginia Legislature Last month, he took action on multiple marijuana bills during a major deadline—advance proposals to legalize the sale of cannabis, provide a way to punish previous marijuana convictions, as well as other laws to allow access to medical cannabis for seriously ill patients in hospitals.

Despite their stark differences, the two chambers’ trade sales bills have largely aligned with recommendations released by the legislature in December. Joint Committee to Oversee the Transition to the Commonwealth Retail Cannabis Market.

Meanwhile, some members of the GOP have aligned ideologically with their Democratic colleagues throughout this legislative process, breaking with the majority of their caucus. in favor of creating a regulated market for adults to buy cannabis.

Since legalizing cannabis ownership and home cultivation in 2021, Virginia lawmakers have been working to establish a commercial marijuana market– Only for those efforts to stall under former Gov. Glenn Youngkin (R), who twice vetoed measures sent to his desk by the Legislature.

Gov. Abigail Spanberger (D), on the other hand, supports legalizing the sale of marijuana to adults.

Separately last month, the Virginia House patients passed a bill to allow the use of medical marijuana in hospitals. It would require health care facilities to implement policies “to address the situation in which an eligible patient is authorized to use medical cannabis.”

The Senate passed various pieces of legislation use of medical cannabis in healthcare facilities last month

—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

Meanwhile, the Virginia House passed the bill earlier this month Protecting the rights of parents who use marijuana by complying with state laws.

Del. According to the proposal by Nadarius Clark (D), a parent or guardian’s own use of cannabis “shall not serve as a basis for a finding of abuse or neglect of a child unless other facts establish that its possession or consumption causes or produces physical or mental injury to the child.”

“A person’s legal possession or consumption of substances permitted (under state marijuana law) shall not serve as a basis for limiting custody or visitation unless other facts establish that such possession or consumption is not in the best interest of the child,” reads the text of HB 942.

Separately, the Virginia Department of Labor and Industry has published a new defining workplace protections for cannabis users.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Continue Reading

Cannabis News

State counties could tax medical marijuana sales under a new House bill

Published

1 day ago

on

March 1, 2026

By











A bill that would allow Oklahoma counties to impose a tax on retail marijuana sales has passed a committee in the Oklahoma House of Representatives.

Under the Oklahoma Legislature, House Bill 3314, authored by Rep. Ryan Eaves, R-Atoka, would allow counties to impose a tax of 15 percent of the impact of public utilities within county boundaries. The bill is similar to Senate Bill 1125, introduced by state Sen. Dusty Deevers, R-Elgin, in the Oklahoma Senate during the 2025 legislative session. SB 1125 would allow counties and municipalities to levy an excise tax on medical marijuana.

HB3314 passed the House County and Municipal Government Committee on a 6-0 vote, and now moves to the Government Oversight Committee for further consideration. The invoice does not automatically generate tax. If a county chooses to join, it must first be approved by a majority of the county’s voters in a special election. The bill also exempts marijuana grown on private property by individuals and not sold.

“Countries are the ones dealing with the daily impact of marijuana sales,” Eaves said. “This allows local communities to decide for themselves whether they want to allocate a portion of that revenue to law enforcement, first responders and improving problem properties.”

Read more at News 9










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media